Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product

MT Newswires Live

02/03

Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.

The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.

The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2608479418"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608479418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608479418?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608479418","market":"nz","top_or_hot":-1,"title":"Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-03 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHY.AU","symbol_name":"RHYTHM BIOSCIENCES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608479418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608479418","pubTimestamp":1770102389,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHY.AU":"RHYTHM BIOSCIENCES LTD","BK7124":"保健护理服务"},"translate_title":"Rhythm Biosciences与美国制造商签订癌症血液检测产品制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":1},"content_text":"Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}